Category: Herbs & Ingredients
The ginkgo and antidepressant question splits into two: a theoretical serotonin concern that rests on thin evidence, and an additive bleeding concern that deserves more respect than the serotonin one. There is also a persistent myth to clear up. Here is how the literature separates them.
Category: Herbs and Ingredients | Reading time: ~12 min | Level: Intermediate
The internet has decided that ginkgo and antidepressants are a dangerous pair, and it is half right in a way that is worth untangling. Two separate worries get bundled together under that headline, and they are not equally solid. One is a serotonin concern, the fear that ginkgo could tip an antidepressant into serotonin syndrome. The other is a bleeding concern, the fear that ginkgo could add to an antidepressant's own effect on bleeding. The first is thin. The second is worth taking seriously. Bundling them makes the strong point look flimsy and the flimsy point look strong, which helps nobody.
There is also a stubborn myth attached to this topic, the warning to never combine ginkgo with an MAOI. It gets repeated so often it sounds settled, but for ginkgo specifically it is poorly supported, and the signal it borrows actually belongs to a different herb. An interaction article that just parrots the myth would be adding noise. This one tries to separate the three threads and grade each honestly.
Everything below is drawn from the published literature and the NIH and European regulatory reviews. It is not a claim generated by any single product or platform.
Ginkgo, botanical name Ginkgo biloba, is a leaf extract taken mostly for memory and circulation, though its evidence for those uses is itself limited [1]. When people ask about ginkgo and antidepressants, they are really asking three questions at once.
The first is whether ginkgo pushes serotonin high enough to matter when added to a serotonergic antidepressant. The second is whether ginkgo's reputation for affecting bleeding stacks with the bleeding tendency that some antidepressants, especially SSRIs, carry. The third is whether specific pairings, such as ginkgo with an MAOI or with trazodone, deserve their own warning. The short version is that the bleeding question is the one with the most substance, the serotonin question is weak, and the MAOI warning is mostly a case of mistaken identity. The rest of this article takes each in turn.
Serotonin syndrome is a genuine and occasionally life-threatening reaction, driven by excessive serotonin activity, and vigilance about it is reasonable whenever serotonergic drugs are combined. So the instinct to ask about it is not silly. The problem is the specific claim that ginkgo causes it.
The evidence tying ginkgo to serotonin syndrome is sparse and indirect. Ginkgo is not primarily a serotonergic agent in the way an SSRI or St John's wort is, and the major evidence reviews do not list serotonin syndrome among ginkgo's established interactions [1]. What you are left with is a theoretical concern rather than a documented pattern. That is worth stating clearly, because if this were the headline risk, the honest grade would be very low. Knowing the symptoms of serotonin syndrome is useful general safety knowledge for anyone on an antidepressant. Attributing that risk firmly to ginkgo is not supported.
Holding this honestly means resisting two temptations: the temptation to scrub the concern entirely, and the temptation to inflate it into a firm rule. It is a low-evidence caution, and that is exactly how it should sit.
This is where the real attention belongs, and it is more interesting than a simple yes or no.
Ginkgo has a genuine set of bleeding case reports behind it. A systematic review by Bent and colleagues in 2005 gathered fifteen published cases of bleeding temporally linked to ginkgo, including several episodes of bleeding within the skull, and concluded there was a possible causal association, while noting that most of those patients had other bleeding risk factors too [3]. Serious spontaneous bleeds are not something to wave away.
But the controlled data tell a calmer story. A meta-analysis by Kellermann and Kloft in 2011, pooling eighteen randomised trials, did not find that standardised ginkgo extract raised bleeding risk, and reported no clinically relevant effect on platelet function or standard clotting tests [4]. European regulators sit in the middle of these two pictures: they formally list bleeding of individual organs as a possible undesirable effect and advise stopping ginkgo 3 to 4 days before surgery, while noting that warfarin studies did not clearly show an interaction and that monitoring is advised [2].
The way to hold both is this. The average person in a trial does not bleed more on ginkgo, but rare, serious, idiosyncratic bleeds have happened, and the downside of one of those is catastrophic. Now add an antidepressant. SSRIs and SNRIs modestly increase bleeding tendency because serotonin is involved in how platelets clump. So the honest concern with ginkgo and an SSRI is additive: two individually small pushes in the same direction, in a person who may also be older, on aspirin, or otherwise prone to bleed. That is a reason to check with a prescriber and pharmacist, particularly around surgery or if other bleeding risks are present, rather than a reason for blanket alarm.
Two named combinations deserve their own mention.
Trazodone is an antidepressant, and there is a published case report of an elderly patient falling into a coma after combining it with ginkgo, discussed in a review of herb-drug interactions by Chen and colleagues [5]. A single case report cannot support a universal rule, and the mechanism proposed involved effects on drug metabolism and sedation rather than bleeding. But it is specific and serious enough that anyone on trazodone should treat ginkgo as a prescriber conversation rather than an afterthought.
The MAOI warning is the myth. You will see it repeated that ginkgo must never be combined with monoamine oxidase inhibitors. For ginkgo specifically, that caution is not well supported in the major regulatory and evidence reviews. The signal it borrows is far better documented for ginseng, a different herb that is frequently confused with ginkgo, including in products that combine the two. Correcting this is not the same as saying MAOIs are relaxed drugs. They are among the most interaction-prone medicines in use, and anyone taking one should clear every supplement with their prescriber. The point is narrower: do not attribute a ginseng caution to ginkgo and call it settled.
There is a habit in supplement safety writing of treating every listed interaction as equally weighty, as though the length of a warning list were a measure of danger. Ginkgo and antidepressants is a good case for resisting that habit, because the two concerns here are genuinely unequal, and flattening them serves nobody.
The serotonin concern is the kind that sounds alarming and evaporates on inspection. It borrows the fear attached to a real syndrome, serotonin syndrome, and attaches it to a herb that has not been shown to cause it. Left unexamined, it does two harms. It frightens people away from a decision they could make calmly, and, worse, it crowds out the concern that actually matters by making the whole topic feel like undifferentiated risk. When everything is flagged as dangerous, nothing is, and the reader stops being able to tell a real caution from a reflexive one.
The bleeding concern is the opposite kind. It sounds mundane, an additive nudge to platelet behaviour, and it is easy to wave away precisely because the controlled trials were mostly reassuring. But it is the one with a documented mechanism, real case reports of catastrophic outcomes, and a regulator-mandated precaution around surgery. Its danger is not that it is common; it is that when it goes wrong, it goes badly wrong, in a person who may already carry other bleeding risks.
Holding these two apart is the whole skill. It means being willing to say, in the same breath, do not lose sleep over serotonin syndrome from ginkgo, and do take the bleeding question to your pharmacist if you are on an SSRI. Those are not contradictory positions. They are what honest, evidence-weighted advice looks like when two concerns of very different strength happen to share a headline. The reader who internalises that distinction is better equipped than the one handed a long, flat list of things to fear.
The practical takeaways follow the evidence rather than the noise.
If you take an antidepressant that affects bleeding, most notably an SSRI or SNRI, treat ginkgo as a bleeding question first. Raise it with your prescriber or pharmacist, name your exact medicine, and mention any other bleeding risks such as aspirin, anticoagulants, older age or a history of bleeds. This is the thread with real evidence behind it.
Stop ginkgo before surgery regardless of your antidepressant, following the standard advice to discontinue it 3 to 4 days beforehand, and tell your surgical team about both the herb and the drug [2].
Do not lose sleep over serotonin syndrome from ginkgo specifically, but do know its warning signs as general safety awareness while on any antidepressant. And do not let the MAOI myth make the decision for you; let your prescriber weigh your actual medication instead.
Finally, if what you want from ginkgo is memory or focus support, it is worth remembering that its evidence even for those uses is limited [1], so for someone already navigating an antidepressant, the risk-to-benefit maths may simply not favour adding it.
Pregnant, breastfeeding, or on medication? Check with a healthcare professional first.
Ginkgo appears in the Remedy Library with its cautions attached, not hidden, because the bleeding signal is part of the honest picture of this leaf rather than a disclaimer to bury. Structure and function only, ginkgo is presented for its traditional role in supporting circulation and cognition, never as a treatment for depression or any mood condition, and never as a substitute for prescribed antidepressant care.
If you are trying to work out whether ginkgo fits alongside your antidepressant, Remy, the PlantRx assistant, can lay out the published bleeding and interaction cautions with their honest grades, separate the well-supported ones from the myths, and point you back to the prescriber conversation the bleeding question really needs.
1. National Center for Complementary and Integrative Health (NCCIH). Ginkgo: Usefulness and Safety. Government evidence and safety review. nccih.nih.gov/health/ginkgo. 2. European Medicines Agency, Committee on Herbal Medicinal Products (HMPC) (2015). European Union herbal monograph on Ginkgo biloba L., folium. EMA/HMPC/321097/2012. Cited for organ bleeding as an undesirable effect, the surgery precaution and the anticoagulant interaction wording. 3. Bent S, Goldberg H, Padula A, Avins AL (2005). Spontaneous bleeding associated with ginkgo biloba: a case report and systematic review of the literature. Journal of General Internal Medicine. PMID 16050865. Fifteen case reports, most with additional bleeding risk factors. 4. Kellermann AJ, Kloft C (2011). Is there a risk of bleeding associated with standardised ginkgo biloba extract therapy? A systematic review and meta-analysis. Pharmacotherapy. PMID 21923430. Eighteen randomised trials; no population-level bleeding increase. 5. Chen XW, Serag ES, Sneed KB, et al. (2011). Clinical herbal interactions with conventional drugs. Current Medicinal Chemistry. PMID 21919844. Cited for the reported ginkgo and trazodone coma case.
This is worth raising with your prescriber, and the reason is bleeding rather than serotonin. SSRIs can increase the tendency to bleed, and ginkgo has case reports of serious bleeds, so the concern is that the two could add together. Controlled trials have not shown ginkgo raising bleeding across a population, which is why this is a caution to discuss rather than an absolute no, especially if you have other bleeding risks.
There is no strong evidence that it does. Serotonin syndrome is a serious reaction driven by too much serotonin activity, and while it is a reasonable thing to be alert to with any serotonergic combination, the specific evidence tying ginkgo to it is thin. It would be dishonest to present this as a documented ginkgo interaction. Bleeding is the better-grounded concern.
This warning circulates widely but is not well supported for ginkgo specifically. The MAOI caution is far better documented for ginseng, which is a different herb, and the two are often confused. That said, MAOIs are unforgiving drugs with many genuine interactions, so anyone taking one should clear every supplement with their prescriber regardless of this particular myth.
There is a published case report of coma in an elderly patient who combined ginkgo with trazodone, thought to involve effects on drug metabolism and sedation. It is a single case, so it cannot carry a blanket rule, but it is specific and serious enough that anyone on trazodone should treat ginkgo as a prescriber conversation rather than a casual addition.
Stopping ginkgo before surgery is standard advice on its own, because of the bleeding caution. European regulators advise discontinuing ginkgo preparations 3 to 4 days before surgery. If you also take an antidepressant that affects bleeding, that advice matters more, not less. Tell your surgical team about both.
It is genuinely mixed. Real case reports describe serious spontaneous bleeds, including bleeding in the brain, while pooled analyses of controlled trials have not found a population-level increase or a meaningful effect on clotting tests. The responsible reading holds both: most people in trials do not bleed more, but rare serious bleeds have been reported, so caution is sensible where other bleeding risks are present.
Because the trials measured average people, and the concern is about stacking risks in a specific person. An SSRI already tips bleeding tendency slightly, and ginkgo's rare serious bleeds happened to real individuals, often ones with other risk factors. Adding two small pushes in the same direction is exactly the situation a null average can hide. It is a reason to check rather than to panic.
It depends on the drug. The bleeding tendency is most associated with SSRIs and SNRIs, which affect platelet function through serotonin. Antidepressants in other classes carry that specific bleeding signal to different degrees. This is precisely the kind of detail your prescriber or pharmacist can pin down for your exact medicine, which is why naming your drug in that conversation matters.
Not baseless, just weak. Being alert to serotonin syndrome with any combination that touches serotonin is good practice, and the symptoms are worth knowing. The honest point is that ginkgo has not been shown to cause it, so it should be held as general vigilance rather than presented as a proven ginkgo interaction. Overstating it would crowd out the bleeding concern that actually deserves attention.